MSO Earnings, State Licensing, and Federal Signals: Week of June 13

MSO Earnings Show Margin Compression Across Tier-One Operators

Curaleaf, Trulieve, and Green Thumb Industries all reported Q2 2026 earnings this week, and the common thread is gross-margin compression despite revenue growth. Curaleaf posted $352 million in revenue (up 4% year-over-year) but gross margin contracted to 41.2% from 44.1% in Q2 2025, driven by price compression in Florida and Illinois. Trulieve reported $298 million in revenue (flat year-over-year) with gross margin sliding to 52.3% from 55.8%, citing Florida wholesale pricing pressure and higher input costs. Green Thumb Industries showed the strongest top-line growth at $287 million (up 7% year-over-year) but gross margin fell to 48.1% from 50.4%, attributed to promotional activity in mature markets.

The thesis here is straightforward: 280E tax burden remains the binding constraint. Without federal reform allowing ordinary business deductions, MSOs are forced to compete on price in saturated markets while absorbing the full cost structure. Curaleaf's effective tax rate hit 71% this quarter. That math is brutal.

All three operators reiterated full-year guidance but lowered EBITDA margin expectations by 100-200 basis points. The Street had already priced in some compression, but the uniform direction across the top tier signals that this is a structural headwind, not a one-quarter anomaly.

Ohio Finalizes Adult-Use Licensing Rules Ahead of October Launch

The Ohio Division of Cannabis Control published final adult-use licensing regulations on June 10, setting a July 15 application deadline for existing medical operators seeking dual licensure and a September 1 lottery for new entrants. The rules allocate 150 new adult-use dispensary licenses statewide, with 50 reserved for social-equity applicants. Existing medical dispensaries (currently 130 active locations) can convert to dual licensure with a $10,000 fee and no competitive application process, a significant advantage for incumbents like Verano, Ayr Wellness, and Cresco Labs.

Social-equity carve-outs require applicants to demonstrate majority ownership by individuals from disproportionately impacted communities and include a reduced $5,000 application fee plus technical-assistance grants. The lottery structure for the remaining 100 general-purpose licenses mirrors Michigan's 2020 rollout, which saw application volumes exceed available slots by 8:1 ratios in metro zones.

Ohio's October 1 launch date positions the state as the eighth adult-use market east of the Mississippi. For context on how state-by-state expansion is reshaping MSO footprints, see the CannIntel topic hub on cannabis news.

Pennsylvania House Advances Adult-Use Bill with Senate Path Uncertain

Pennsylvania's House of Representatives passed HB 2500 on June 11 by a 107-96 vote, advancing adult-use legalization to the Senate where Republican leadership has signaled skepticism. The bill authorizes possession of up to one ounce, establishes a 10% excise tax on top of the existing 6% sales tax, and allocates 200 new retail licenses with a 25% social-equity reserve. Existing medical dispensaries (currently 180 locations operated by 17 vertically integrated permittees) would receive automatic dual licensure.

Senate Majority Leader issued a statement the same day calling the bill "premature" and citing concerns over impaired-driving enforcement and workplace-safety standards. The legislative calendar shows 12 session days remaining before the August recess. That's a narrow window for floor action. If the bill stalls in committee, proponents have indicated they'll attempt to attach it as an amendment to the budget reconciliation package in September.

Pennsylvania represents a $1.8 billion annual adult-use market opportunity according to legislative fiscal notes, making it the largest East Coast state yet to legalize. The political variable nobody can model is whether Governor Shapiro will expend capital to pressure Senate Republicans during budget negotiations.

DEA Rescheduling Review Remains in Administrative Limbo

DEA Acting Administrator Timothy Shea told a Senate Appropriations subcommittee on June 12 that the agency's review of the HHS recommendation to reschedule cannabis to Schedule III is "ongoing" with no finalized timeline for a Notice of Proposed Rulemaking. HHS submitted its scientific evaluation to DEA in August 2023, initiating a statutory review process that typically concludes within 90-180 days. The current delay—approaching 34 months—is without recent precedent in Controlled Substances Act rescheduling actions.

Shea's testimony indicated that DEA is conducting supplemental consultations with the FDA and NIDA regarding abuse-potential data, a step not outlined in the standard rescheduling protocol. He declined to commit to a publication date for the NPRM, stating only that the review is "comprehensive and deliberate."

Here's the practical implication: MSOs and investors pricing in near-term 280E relief via Schedule III rescheduling should recalibrate expectations. Even if DEA publishes an NPRM in Q3 2026, the public-comment period and final-rule process would push implementation into 2027 at the earliest.

What to Watch in the Week Ahead

The next signal: Pennsylvania Senate committee hearings on HB 2500 are scheduled for June 18-19, and any markup activity will clarify whether the bill has a path to a floor vote before recess. On the federal side, the Senate Finance Committee has scheduled a June 20 hearing on cannabis taxation policy, where Treasury officials are expected to address 280E enforcement and potential administrative relief mechanisms.

Ohio's July 15 dual-licensure application deadline will also be a key milestone. Watch for incumbent MSOs to disclose their conversion filings in upcoming 10-Q reports. For operators with Ohio exposure, the dual-license pathway represents immediate adult-use revenue access without competitive-application risk, a rare structural advantage in state-level rollouts.